Biotechnology company Tiziana Life Sciences, Ltd. (TLSA) announced Monday the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. Elrifi succeeds Gabriele Cerrone, who was acting CEO and will now remain in his role as Executive Chairman of the board.Ivor was formerly the global head of the Patent Group at Cooley since 2014 and before that the global head of Patents at Mintz Levin from 1999 to 2014.He has counseled companies in various key industries, including pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, universities, hospitals and governments throughout the world, particularly in the US and Europe..

生物技术公司Tiziana Life Sciences，Ltd.（TLSA）周一宣布任命Ivor Elrifi为首席执行官（CEO），立即生效。Elrifi接替GabrieleCerrone，后者曾是代理首席执行官，现在将继续担任董事会执行主席。自2014年以来，Ivor曾任Cooley专利集团全球负责人，在此之前，他于1999年至2014年任Mintz Levin专利集团全球负责人。他曾为多个关键行业的公司提供咨询，包括制药、生物技术、生命科学和医疗器械公司、研究机构、大学、医院和政府，尤其是美国和欧洲的公司。。

Ivor has extensive experience in advising clients on strategic transactional work and regularly counsels' clients with respect to investments, business development and mergers and acquisitions, including acquisition transactions involving Novartis, Eli Lilly, Biogen and Astellas. For comments and feedback contact: editorial@rttnews.comBusiness News.

Ivor在为客户提供战略交易工作咨询方面拥有丰富的经验，并定期为客户提供投资、业务发展和并购方面的咨询，包括涉及诺华、礼来、比根和阿斯特拉斯的收购交易。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股